公开(公告)号：US20180363066A1

公开(公告)日：2018-12-20

申请号：US16115373

申请日：2018-08-28

申请人： Foundation Medicine, Inc. ,  Genentech, Inc.

发明人： Zachary R. Chalmers ,  Caitlin F. Connelly ,  David Fabrizio ,  Garrett Michael Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky

IPC分类号： C12Q1/6886 ,  C12Q1/6806 ,  C12Q1/6827

摘要： Methods of evaluating tumor mutational burden in a sample, e.g., a tumor sample or a sample derived from a tumor, from a subject, are disclosed.

公开(公告)号：US11300570B2

公开(公告)日：2022-04-12

申请号：US16371589

申请日：2019-04-01

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC分类号： G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61K39/00

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20190219586A1

公开(公告)日：2019-07-18

申请号：US16371589

申请日：2019-04-01

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： David Fabrizio ,  Garrett M. Frampton ,  Priti Hegde ,  Marcin Kowanetz ,  David Shames ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky ,  Wei Zou

IPC分类号： G01N33/574 ,  A61P35/00 ,  C07K16/28 ,  C07K14/705 ,  A61K45/06 ,  C12Q1/6886 ,  A61K39/395 ,  A61K38/17 ,  A61P35/04

CPC分类号： G01N33/57492 ,  A61K38/1774 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55 ,  A61P35/00 ,  A61P35/04 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70596 ,  G01N2800/52

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US11279767B2

公开(公告)日：2022-03-22

申请号：US16115343

申请日：2018-08-28

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： Richard Bourgon ,  David Fabrizio ,  Gregg Fine ,  Garrett M. Frampton ,  Priti Hegde ,  Sanjeev Mariathasan ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky

IPC分类号： C07K16/28 ,  A61K39/395 ,  G16H20/10 ,  G16H50/30 ,  A61K39/00

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20190032151A1

公开(公告)日：2019-01-31

申请号：US16157853

申请日：2018-10-11

申请人： Genentech, Inc.

发明人： Jeffrey Wallin ,  Priti Hegde

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  C07K16/22 ,  C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61P35/00

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, kidney cancer. The invention provides, inter alia, methods of treating cancer and methods of monitoring the response of a patient having a cancer to treatment with an anti-cancer therapy comprising a VEGF antagonist (e.g., an anti-VEGF antibody) and a PD-L1 axis binding antagonist (e.g., an anti-PD-L1 antibody).

公开(公告)号：US11535671B2

公开(公告)日：2022-12-27

申请号：US16655495

申请日：2019-10-17

申请人： Genentech, Inc.

发明人： Priti Hegde ,  Marcin Kowanetz ,  Gregg Fine ,  Sanjeev Mariathasan ,  Richard Bourgon

IPC分类号： C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  A61K39/00

摘要： The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US11299544B2

公开(公告)日：2022-04-12

申请号：US14850462

申请日：2015-09-10

申请人： Genentech, Inc.

发明人： Daniel Shin-Yu Chen ,  Priti Hegde ,  Hartmut Koeppen ,  Marcin Kowanetz

IPC分类号： G01N33/574 ,  A61K39/00 ,  C07K16/28 ,  C12Q1/6886 ,  G01N33/68 ,  G06Q30/02

摘要： Provided herein are biomarkers for the treatment of pathological conditions, such as cancer, and method of using PD-1/PD-L1 pathway antagonists. In particular, provided are biomarkers for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

公开(公告)号：US12078638B2

公开(公告)日：2024-09-03

申请号：US17835418

申请日：2022-06-08

申请人： Genentech, Inc.

发明人： Priti Hegde ,  Mahrukh Huseni

IPC分类号： C12Q1/6886 ,  A61K31/404 ,  A61K39/395 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

CPC分类号： G01N33/5748 ,  A61K31/404 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/04 ,  C07K16/22 ,  C07K16/2827 ,  C12Q1/6886 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

公开(公告)号：US11236394B2

公开(公告)日：2022-02-01

申请号：US15609473

申请日：2017-05-31

申请人： Genentech, Inc.

发明人： Luciana Molinero ,  Priti Hegde

IPC分类号： C12Q1/6886

摘要： The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.

公开(公告)号：US20150056190A1

公开(公告)日：2015-02-26

申请号：US14388565

申请日：2013-03-14

申请人： Genentech, Inc.

发明人： Priti Hegde ,  Maike Schmidt ,  Ru-Fang Yeh

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07K16/22

CPC分类号： C12Q1/6886 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/47 ,  G01N2333/515 ,  G01N2333/70596 ,  G01N2333/7456 ,  G01N2333/755 ,  G01N2333/90254

摘要： The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

摘要翻译： 本发明提供了检测一种或多种生物标志物的表达的方法和组合物，用于鉴定和治疗可能对VEGF拮抗剂治疗有反应的患者。 本发明还提供用于该方法的试剂盒和制品。